REGENXBIO Reports Positive Phase 3 Results for RGX-202 in Duchenne Muscular Dystrophy

REGENXBIO has announced positive topline results from the pivotal Phase 3 portion of its AFFINITY DUCHENNE trial evaluating investigational gene therapy RGX-202 in patients with Duchenne Muscular Dystrophy (DMD).

The company reported that the study achieved its primary endpoint with high statistical significance, marking a major milestone in the development of RGX-202 as a potential treatment for one of the most severe inherited neuromuscular disorders.

RGX-202 Demonstrates Strong Microdystrophin Expression

According to REGENXBIO, 93% of participants treated with RGX-202 achieved microdystrophin expression levels above 10% at Week 12, meeting the trial’s primary endpoint with a p-value of less than 0.0001.

The Phase 1/2/3 AFFINITY DUCHENNE trial enrolled ambulatory boys aged one year and older with Duchenne muscular dystrophy.

Key topline findings included:

• Average microdystrophin expression of 71.1% across all participants
• Average expression of 41.6% in boys older than 8 years
• 80% of participants achieving expression levels above 40%

The company also reported a statistically significant correlation between microdystrophin expression and functional improvement in patients assessed one year after treatment.

Functional Improvements Observed in Interim Analysis

Interim functional data were evaluated in nine participants older than four years who completed one year of follow-up after receiving RGX-202.

According to the company, higher microdystrophin expression levels were associated with improvements in functional measures, including the North Star Ambulatory Assessment (NSAA), a widely used tool for evaluating motor abilities in DMD patients.

The findings are particularly important because demonstrating both protein expression and functional benefit remains a key goal for gene therapy programs in Duchenne muscular dystrophy.

Favorable Safety Profile Reported

REGENXBIO stated that RGX-202 was generally well tolerated and showed a favorable interim safety profile.

The company reported:

• No new safety concerns
• Manageable tolerability findings
• Continued monitoring across ongoing trial cohorts

The safety profile remains an important factor in DMD gene therapy development, where immune-related adverse events and liver toxicity have historically been areas of concern across the field.

Why Duchenne Muscular Dystrophy Remains a Major Unmet Need?

Duchenne muscular dystrophy is a rare genetic disease caused by mutations in the dystrophin gene, resulting in progressive muscle degeneration and weakness.

The disease primarily affects boys and typically leads to:

• Loss of ambulation
• Respiratory complications
• Cardiac dysfunction
• Reduced life expectancy

Current treatment options remain limited, and many investigational gene therapies are focused on delivering shortened versions of dystrophin, known as microdystrophin, to help restore muscle function.

What Differentiates RGX-202?

According to REGENXBIO, RGX-202 incorporates several differentiated design features intended to improve durability and therapeutic performance.

These include:

• A novel microdystrophin construct containing the C-terminal domain
• A proactive immune suppression regimen
• A suspension-based manufacturing process designed to enhance purity and consistency

The company believes these features may contribute to stronger and potentially more durable therapeutic outcomes.

Expert and Patient Community Reactions

Dr. Aravindhan Veerapandiyan, principal investigator for the AFFINITY DUCHENNE trial at Arkansas Children's Hospital, highlighted the significance of the findings.

According to Dr. Veerapandiyan, the combination of robust microdystrophin expression, functional correlation, and manageable safety findings is encouraging for the Duchenne community.

Meanwhile, Parent Project Muscular Dystrophy founder and president Pat Furlong described the results as a source of renewed optimism for families affected by DMD.

Regulatory Plans and Next Steps

REGENXBIO stated that the topline results support plans for a potential accelerated approval filing in 2027.

The company also reported that:

• More than 20 patients have already enrolled in the confirmatory portion of the study
• Dosing is expected to be completed in all 60 participants across pivotal and confirmatory cohorts by mid-2026

Additional data from the AFFINITY DUCHENNE trial are expected to be presented at upcoming scientific conferences and included in future regulatory submissions.

What This Means for the DMD Gene Therapy Landscape?

The positive Phase 3 findings position RGX-202 as an important emerging contender in the competitive Duchenne gene therapy space.

The combination of:

• High microdystrophin expression
• Functional correlation
• Favorable safety profile
• Potential accelerated approval pathway

could strengthen REGENXBIO’s position as the company advances toward regulatory discussions.

If future data continue to support durable functional benefits, RGX-202 may represent a meaningful advancement for patients and families living with Duchenne muscular dystrophy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!